title: Biologics in inflammatory disease: infliximab associated risk of lymphoma development.
authors.forename: C
authors.initials: C
authors.lastname: Bucher
authors.forename: L
authors.initials: L
authors.lastname: Degen
authors.forename: S
authors.initials: S
authors.lastname: Dirnhofer
authors.forename: M
authors.initials: M
authors.lastname: Pless
authors.forename: R
authors.initials: R
authors.lastname: Herrmann
authors.forename: P
authors.initials: P
authors.lastname: Schraml
authors.forename: P
authors.initials: P
authors.lastname: Went
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab